At the same time, with the virus resurgent, public health experts are warning Americans not to let their guards down. The United States is averaging more than 67,000 new cases a day over the past seven days, up from over 54,000 a month ago, according to a New York Times database.
“Seventy thousand cases a day is not acceptable. We have to get that down,” said Barry Bloom, a research professor and former dean of the Harvard T.H. Chan School of Public Health. He said more vaccinations would help, but people must remain vigilant about wearing masks and social distancing.
- On April 13, 2021, U.S. health agencies called for an immediate pause in the use of Johnson & Johnson’s single-dose Covid-19 vaccine after six recipients in the United States developed a rare disorder involving blood clots within one to three weeks of vaccination.
- All 50 states, Washington, D.C. and Puerto Rico temporarily halted or recommended providers pause the use of the vaccine. The U.S. military, federally run vaccination sites and a host of private companies, including CVS, Walgreens, Rite Aid, Walmart and Publix, also paused the injections.
- Fewer than one in a million Johnson & Johnson vaccinations are now under investigation. If there is indeed a risk of blood clots from the vaccine — which has yet to be determined — that risk is extremely low. The risk of getting Covid-19 in the United States is far higher.
- The pause could complicate the nation’s vaccination efforts at a time when many states are confronting a surge in new cases and seeking to address vaccine hesitancy.
- Johnson & Johnson has also decided to delay the rollout of its vaccine in Europe amid concerns over rare blood clots, dealing another blow to Europe’s inoculation push. South Africa, devastated by a more contagious virus variant that emerged there, suspended use of the vaccine as well. Australia announced it would not purchase any doses.
At its current pace, the United States will vaccinate 70 percent of its population by mid-June. But vaccine hesitancy could slow progress toward herd immunity, which will also depend on vaccinating children.
Pfizer announced this month that it had applied for an emergency use authorization to make children ages 12 to 15 eligible for its vaccine. Moderna is expected to release results from its trial in young teenagers soon, and vaccinations in this age group could begin before school starts in the fall.
Trials in younger children are underway. Dr. Fauci also said on Sunday that he expected children of all ages to be eligible for vaccination in the first quarter of 2022.
Although vaccinations have picked up in the United States, many countries still face dire vaccine shortages. About 83 percent of Covid-19 vaccinations have been administered in high- and upper-middle-income countries, while only 0.2 percent of doses have been administered in low-income countries, according to a New York Times vaccine tracker.
Dr. Funmi Olopade, the director of the Center for Global Health at the University of Chicago, said it was crucial for the United States to step up its role in the global vaccination campaign as supply increases. The virus, left to spread around the world, could continue to mutate and threaten the nation’s economic recovery, she said.
It is in everybody’s “self-interest to provide whatever we can in the way of excess vaccines to low- and middle-income countries,” Dr. Bloom said.